Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Karagianni F, Njauw CN, Kypreou KP, Stergiopoulou A, Plaka M, Polydorou D, Chasapi V, Pappas L, Stratigos IA, Champsas G, Panagiotou P, Gogas H, Evangelou E, Tsao H, Stratigos AJ, Stefanaki I. Karagianni F, et al. Among authors: chasapi v. Acta Derm Venereol. 2018 Oct 10;98(9):862-866. doi: 10.2340/00015555-2969. Acta Derm Venereol. 2018. PMID: 29774366 Free PMC article.
Factitious Disorder as a Skin Ulcer: A Case Report.
Kontoangelos K, Kousta F, Potouridou I, Chasapi V, Dikeos D, Stratigos A. Kontoangelos K, et al. Among authors: chasapi v. Cureus. 2024 Jan 4;16(1):e51642. doi: 10.7759/cureus.51642. eCollection 2024 Jan. Cureus. 2024. PMID: 38313954 Free PMC article.
Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis.
Rompoti N, Stefanaki I, Panagakis P, Papoutsaki M, Politou M, Vavouli C, Befon A, Kousta F, Lazou E, Zaimi M, Koumprentziotis IA, Chasapi V, Rigopoulos D, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: chasapi v. J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e1-e4. doi: 10.1111/jdv.19956. Epub 2024 Mar 20. J Eur Acad Dermatol Venereol. 2025. PMID: 38506605 No abstract available.
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.
Rompoti N, Vergou T, Stefanaki I, Vavouli C, Koumprentziotis IA, Panagakis P, Papoutsaki M, Politou M, Befon A, Kousta F, Lazou E, Zaimi M, Chasapi V, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: chasapi v. Int J Dermatol. 2024 Oct;63(10):e255-e258. doi: 10.1111/ijd.17400. Epub 2024 Jul 25. Int J Dermatol. 2024. PMID: 39051109 No abstract available.
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.
Rompoti N, Koumprentziotis IA, Stefanaki I, Vavouli C, Papoutsaki M, Politou M, Panagakis P, Befon A, Kousta F, Lazou E, Chasapi V, Stratigos A, Nicolaidou E. Rompoti N, et al. Among authors: chasapi v. Arch Dermatol Res. 2024 Oct 9;316(9):667. doi: 10.1007/s00403-024-03419-w. Arch Dermatol Res. 2024. PMID: 39382588 No abstract available.
43 results